Mesoblast Corporate Presentation at Investor Conference [Yahoo! Finance]
Mesoblast Limited - American Depositary Shares (MESO)
US:NASDAQ Investor Relations:
investorsmedia.mesoblast.com
Company Research
Source: Yahoo! Finance
Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Application (BLA) resubmission with the United States Food and Drug Administration (FDA) for its lead product candidate Ryoncil ® (remestemcel-L) in the treatment of steroid-refractory acute graft versus host disease, with potential approval in the second half of CY2024. Dr. Itescu additionally highlighted the heart failure and back pain programs in Phase 3, and the recent feedback from FDA regarding an accelerated approval pathway for the heart failure product Revascor ® (rexlemestrocel). The presentation also highlighted Mesoblast's strong United States intellectual property position, with granted patents through 2032 covering mesenchymal stem cell compositions of matter, irrespective of source, and their broad uses, including for GVHD. On RYONCIL approval, the granted patents may be extended up to 2037. Additional patent filings may extend the commercial barrier to entry through 2043. T
Show less
Read more
Impact Snapshot
Event Time:
MESO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MESO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MESO alerts
High impacting Mesoblast Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MESO
News
- Mesoblast Limited (NASDAQ: MESO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- ASX Growth Companies With High Insider Ownership To Watch In June 2024 [Yahoo! Finance]Yahoo! Finance
- Three ASX Growth Companies With High Insider Ownership And Earnings Growth Up To 120% [Yahoo! Finance]Yahoo! Finance
- High Insider Ownership Growth Stocks On The ASX In June 2024 [Yahoo! Finance]Yahoo! Finance
- Exploring Three ASX Growth Companies With Significant Insider Ownership [Yahoo! Finance]Yahoo! Finance